A phase IB, open label, single center, drug-drug interaction study of oral 1250 mg of PTK787/ZK 222584 [vatalanib] administered under fasting and fed conditions with a proton-pump inhibitor (omeprazole) in healthy sterile or postmenopausal female volunteers.
Phase of Trial: Phase I
Latest Information Update: 29 Sep 2009
At a glance
- Drugs Vatalanib (Primary) ; Omeprazole
- Indications Age-related macular degeneration; Colorectal cancer; Gastro-oesophageal reflux; Glioblastoma; Multiple myeloma; Non-small cell lung cancer; Ovarian cancer; Renal cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Novartis
- 17 Feb 2007 New trial record.